11/29
01:39 pm
imvt
Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings [Yahoo! Finance]
Medium
Report
Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings [Yahoo! Finance]
11/10
04:41 pm
imvt
Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025 [Yahoo! Finance]
Low
Report
Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025 [Yahoo! Finance]
11/10
07:10 am
imvt
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update [Yahoo! Finance]
Low
Report
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update [Yahoo! Finance]
11/10
07:00 am
imvt
Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025
Low
Report
Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025
10/27
04:10 pm
imvt
Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
Low
Report
Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
10/14
12:15 pm
imvt
Immunovant (NASDAQ:IMVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Immunovant (NASDAQ:IMVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/14
07:00 am
imvt
Immunovant (NASDAQ:IMVT) was given a new $16.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Immunovant (NASDAQ:IMVT) was given a new $16.00 price target on by analysts at Truist Financial Corporation.
10/8
01:09 am
imvt
JPMorgan Lowers PT on Immunovant (IMVT) to $33 From $37 [Yahoo! Finance]
Low
Report
JPMorgan Lowers PT on Immunovant (IMVT) to $33 From $37 [Yahoo! Finance]
9/30
08:38 am
imvt
Immunovant (NASDAQ:IMVT) had its price target lowered by analysts at JPMorgan Chase & Co. from $37.00 to $33.00. They now have an "overweight" rating on the stock.
Low
Report
Immunovant (NASDAQ:IMVT) had its price target lowered by analysts at JPMorgan Chase & Co. from $37.00 to $33.00. They now have an "overweight" rating on the stock.
9/30
04:10 am
imvt
Where is Immunovant (IMVT) Heading According to Analysts? [Yahoo! Finance]
Low
Report
Where is Immunovant (IMVT) Heading According to Analysts? [Yahoo! Finance]
9/25
02:50 am
imvt
Roivant Sciences Ltd. (ROIV) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Roivant Sciences Ltd. (ROIV) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript [Seeking Alpha]
9/17
05:29 pm
imvt
IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT
Low
Report
IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT
9/12
04:22 pm
imvt
IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT
Medium
Report
IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT
9/10
08:55 am
imvt
Patient Recruitment Strategies: Empowering Patients Through Accessible Information, Upcoming Webinar Hosted by Xtalks [Yahoo! Finance]
Low
Report
Patient Recruitment Strategies: Empowering Patients Through Accessible Information, Upcoming Webinar Hosted by Xtalks [Yahoo! Finance]